U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C18H17Cl2FN4OS.ClH
Molecular Weight 463.784
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of AFURESERTIB HYDROCHLORIDE

SMILES

Cl.CN1N=CC(Cl)=C1C2=C(Cl)SC(=C2)C(=O)N[C@H](CN)CC3=CC=CC(F)=C3

InChI

InChIKey=YFQJOPFTGMHYNV-YDALLXLXSA-N
InChI=1S/C18H17Cl2FN4OS.ClH/c1-25-16(14(19)9-23-25)13-7-15(27-17(13)20)18(26)24-12(8-22)6-10-3-2-4-11(21)5-10;/h2-5,7,9,12H,6,8,22H2,1H3,(H,24,26);1H/t12-;/m0./s1

HIDE SMILES / InChI

Molecular Formula ClH
Molecular Weight 36.461
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C18H17Cl2FN4OS
Molecular Weight 427.323
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 1 / 1
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment: Description was created based on several sources, including http://www.bloodjournal.org/content/118/21/1856 http://adisinsight.springer.com/drugs/800033693

Afuresertib (GSK2110183 ) is an orally bioavailable inhibitor of the serine/threonine protein kinase Akt (protein kinase B) with potential antineoplastic activity. Afuresertib binds to and inhibits the activity of Akt, which may result in inhibition of the PI3K/Akt signaling pathway and tumor cell proliferation and the induction of tumor cell apoptosis. Activation of the PI3K/Akt signaling pathway is frequently associated with tumorigenesis and dysregulated PI3K/Akt signaling may contribute to tumor resistance to a variety of antineoplastic agents. Preclinically, AKT inhibition by afuresertib can reverse platinum resistance in ovarian cancer cell lines isolated from patients with platinum-resistant ovarian cancer. Afuresertib is well tolerated and demonstrates clinical activity as monotherapy in heavily pretreated MM patients. Is in phase II clinical trials for Chronic lymphocytic leukaemia; Haematological malignancies; Histiocytosis.

Approval Year

Targets

Targets

Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
949 ng/mL
150 mg 1 times / day multiple, oral
dose: 150 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
AFURESERTIB plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
554 ng/mL
100 mg 1 times / day multiple, oral
dose: 100 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
AFURESERTIB plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
531 ng/mL
125 mg 1 times / day multiple, oral
dose: 125 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
AFURESERTIB plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
13425 ng × h/mL
150 mg 1 times / day multiple, oral
dose: 150 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
AFURESERTIB plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
6782 ng × h/mL
100 mg 1 times / day multiple, oral
dose: 100 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
AFURESERTIB plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
7405 ng × h/mL
125 mg 1 times / day multiple, oral
dose: 125 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
AFURESERTIB plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG



OverviewOther

Other InhibitorOther SubstrateOther Inducer


Drug as perpetrator​
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Discovery of novel AKT inhibitors with enhanced anti-tumor effects in combination with the MEK inhibitor.
2014
Phase I study of the MEK inhibitor trametinib in combination with the AKT inhibitor afuresertib in patients with solid tumors and multiple myeloma.
2015 Jan
A phase IIa study of afuresertib, an oral pan-AKT inhibitor, in patients with Langerhans cell histiocytosis.
2017 May
Patents

Sample Use Guides

Seventy-three patients were treated at doses ranging from 25 to 150 mg per day. The MTD was established at 125 mg per day
Route of Administration: Oral
Afuresertib inhibits the kinase activity of the E17K AKT1 mutant protein with EC50 of 0.2 nM. Afuresertib shows a concentration-dependent effect on multiple AKT substrate phosphorylation levels, including GSK3b, PRAS40, FOXO and Caspase 9. Overall 65% of the hematological cell lines are sensitive to afuresertib (EC50 < 1 uM).
Substance Class Chemical
Created
by admin
on Fri Dec 15 16:45:46 GMT 2023
Edited
by admin
on Fri Dec 15 16:45:46 GMT 2023
Record UNII
0FC27E442O
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
AFURESERTIB HYDROCHLORIDE
USAN   WHO-DD  
USAN  
Official Name English
2-THIOPHENECARBOXAMIDE, N-((1S)-2-AMINO-1-((3-FLUOROPHENYL)METHYL)ETHYL)-5-CHLORO-4-(4-CHLORO-1-METHYL-1H-PYRAZOL-5-YL)-, HYDROCHLORIDE (1:1)
Systematic Name English
Afuresertib hydrochloride [WHO-DD]
Common Name English
N-[(1S)-1-(Aminomethyl)-2-(3-fluorophenyl)ethyl]-5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)thiophene-2-carboxamide monohydrochloride
Systematic Name English
GSK-2110183B
Code English
GSK2110183B
Code English
AFURESERTIB HYDROCHLORIDE [USAN]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C61074
Created by admin on Fri Dec 15 16:45:46 GMT 2023 , Edited by admin on Fri Dec 15 16:45:46 GMT 2023
Code System Code Type Description
DRUG BANK
DBSALT002037
Created by admin on Fri Dec 15 16:45:46 GMT 2023 , Edited by admin on Fri Dec 15 16:45:46 GMT 2023
PRIMARY
USAN
ZZ-03
Created by admin on Fri Dec 15 16:45:46 GMT 2023 , Edited by admin on Fri Dec 15 16:45:46 GMT 2023
PRIMARY
EPA CompTox
DTXSID20146712
Created by admin on Fri Dec 15 16:45:46 GMT 2023 , Edited by admin on Fri Dec 15 16:45:46 GMT 2023
PRIMARY
CAS
1047645-82-8
Created by admin on Fri Dec 15 16:45:46 GMT 2023 , Edited by admin on Fri Dec 15 16:45:46 GMT 2023
PRIMARY
SMS_ID
300000044612
Created by admin on Fri Dec 15 16:45:46 GMT 2023 , Edited by admin on Fri Dec 15 16:45:46 GMT 2023
PRIMARY
FDA UNII
0FC27E442O
Created by admin on Fri Dec 15 16:45:46 GMT 2023 , Edited by admin on Fri Dec 15 16:45:46 GMT 2023
PRIMARY
PUBCHEM
46843056
Created by admin on Fri Dec 15 16:45:46 GMT 2023 , Edited by admin on Fri Dec 15 16:45:46 GMT 2023
PRIMARY
ChEMBL
CHEMBL2219422
Created by admin on Fri Dec 15 16:45:46 GMT 2023 , Edited by admin on Fri Dec 15 16:45:46 GMT 2023
PRIMARY
NCI_THESAURUS
C142902
Created by admin on Fri Dec 15 16:45:46 GMT 2023 , Edited by admin on Fri Dec 15 16:45:46 GMT 2023
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY